Assessing United Laboratories International Holdings (SEHK:3933) Valuation After Positive UBT251 Phase 2 Trial Results

Simply Wall St.04-08

AdvertisementPhase 2 data on UBT251 puts United Laboratories International Holdings in focus United Laboratories International Holdings (SEHK:3933) drew investor attention after releasing phase 2 data...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2625947028?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-04-08 18:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625947028","market":"nz","top_or_hot":-1,"title":"Assessing United Laboratories International Holdings (SEHK:3933) Valuation After Positive UBT251 Phase 2 Trial Results","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementPhase 2 data on UBT251 puts United Laboratories International Holdings in focus United Laboratories International Holdings (SEHK:3933) drew investor attention after releasing phase 2 data...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3933/united-laboratories-international-holdings-shares/news/assessing-united-laboratories-international-holdings-sehk393-1\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing United Laboratories International Holdings (SEHK:3933) Valuation After Positive UBT251 Phase 2 Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing United Laboratories International Holdings (SEHK:3933) Valuation After Positive UBT251 Phase 2 Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-08 18:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3933/united-laboratories-international-holdings-shares/news/assessing-united-laboratories-international-holdings-sehk393-1><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementPhase 2 data on UBT251 puts United Laboratories International Holdings in focus United Laboratories International Holdings (SEHK:3933) drew investor attention after releasing phase 2 data...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3933/united-laboratories-international-holdings-shares/news/assessing-united-laboratories-international-holdings-sehk393-1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"UBCP","symbol_name":"联合合众银行","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3933/united-laboratories-international-holdings-shares/news/assessing-united-laboratories-international-holdings-sehk393-1","article_id":"2625947028","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3933/united-laboratories-international-holdings-shares/news/assessing-united-laboratories-international-holdings-sehk393-1","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2625947028","pubTimestamp":1775644137,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Phase 2 data on UBT251 puts United Laboratories International Holdings in focus\nUnited Laboratories International Holdings (SEHK:3933) drew investor attention after releasing phase 2 data for UBT251 in China, showing HbA1c and body weight reductions against placebo and semaglutide in type 2 diabetes patients.\nThe topline readout matters because it moves UBT251 closer to late stage development, supports the start of phase 3 trials in China, and ties directly into the company’s broader diabetes...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"UBCP":"联合合众银行","03933":"联邦制药","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK1191":"制药","BK4211":"区域性银行"},"translate_title":"在UBT251 2期试验结果积极后评估联邦制药国际控股公司（SEHK：3933）的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UBCP":1.5,"DCF":1,"03933":0.9},"content_text":"AdvertisementPhase 2 data on UBT251 puts United Laboratories International Holdings in focus United Laboratories International Holdings (SEHK:3933) drew investor attention after releasing phase 2 data for UBT251 in China, showing HbA1c and body weight reductions against placebo and semaglutide in type 2 diabetes patients. The topline readout matters because it moves UBT251 closer to late stage development, supports the start of phase 3 trials in China, and ties directly into the company’s broader diabetes and metabolic disease franchise. See our latest analysis for United Laboratories International Holdings. Despite the positive UBT251 update, the recent 30 day share price return of 19.6% and year to date share price return decline of 10.83% contrast with a much stronger 3 year total shareholder return of 117.16%. This suggests that longer term momentum remains intact even as shorter term sentiment has cooled. If this kind of clinical news has your attention, it can be helpful to see what else is moving in related areas of the market, starting with 128 healthcare AI stocks With United Laboratories reporting HK$13,210.6m in revenue and HK$2,085.9m in net income, and currently trading about 60% below one intrinsic value estimate and 55% below one analyst target, is this pricing in risk or highlighting a potential opportunity related to future growth? Price-to-Earnings of 8.6x: Is it justified? On a simple P/E view, United Laboratories International Holdings at 8.6x earnings looks cheap compared to both its peers and what one fair value model suggests, even with recent share price weakness. The P/E ratio compares the current share price to earnings per share and is a quick way to see how much investors are paying for each unit of profit. For a profitable pharmaceutical group with HK$13,210.6m in revenue and HK$2,085.9m in net income, this measure helps you weigh current pricing against the earnings power already on the table. Analysts see earnings growing at 9.4% per year and revenue at 5.4% per year, which is slower than the wider Hong Kong market forecasts, while Return on Equity is expected to sit at 11%. That mix of moderate growth expectations and a low P/E can suggest the market is cautious on how durable recent profitability is. This is especially the case with profit margins at 15.8% compared to 19.3% last year, and earnings declining over the past year despite strong 5 year earnings growth. The gap becomes clearer when compared with the Hong Kong Pharmaceuticals industry average P/E of 15.4x and an estimated fair P/E of 20.4x for United Laboratories. The current 8.6x multiple sits well below both levels, a spread that some investors may see as room for the valuation multiple to move closer to what the fair ratio model suggests. Explore the SWS fair ratio for United Laboratories International Holdings Result: Price-to-Earnings of 8.6x (UNDERVALUED) However, the recent 1 year total return decline of 11.1% and earnings contraction over the past year highlight execution and sentiment risks that could limit any rerating. Find out about the key risks to this United Laboratories International Holdings narrative. Another way to look at value While the 8.6x P/E suggests United Laboratories International Holdings is cheap, the SWS DCF model paints an even starker picture. With the shares at HK$10.46 and one DCF estimate at HK$25.96, the implied discount raises a simple question: is the market too cautious or seeing risks that the model cannot? Look into how the SWS DCF model arrives at its fair value. 3933 Discounted Cash Flow as at Apr 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out United Laboratories International Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 234 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps Given the mix of cautious signals and potential upside in this story, it may be helpful to act promptly and review the full picture for yourself, starting with the 4 key rewards and 1 important warning sign. Looking for more investment ideas? If you stop here, you only see part of what is available. Use the tools at hand and give yourself the chance to spot your next strong idea.  Target resilient opportunities with lower risk by reviewing the 299 resilient stocks with low risk scores, which screens for stocks with more robust risk profiles. Hunt for quality at a discount by checking the 234 high quality undervalued stocks, which highlights companies combining stronger fundamentals with more modest valuations. Prioritise income potential by scanning the 488 dividend fortresses, which focuses on higher yielding dividend payers.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2625947028","isCrawlerRequest":true}